Stockscreener 앱 받기
0.4948
3.10%
0.0149
시간 외 거래:
.49
-0.0048
-0.97%
전일 마감가:
$0.4799
열려 있는:
$0.47
하루 거래량:
1.10M
Relative Volume:
0.50
시가총액:
$46.69M
수익:
-
순이익/손실:
$-30.54M
주가수익비율:
-0.2499
EPS:
-1.98
순현금흐름:
$-18.30M
1주 성능:
+2.68%
1개월 성능:
+32.41%
6개월 성능:
-55.82%
1년 성능:
-17.40%
1일 변동 폭
$0.451
$0.50
1주일 범위
$0.451
$0.549
52주 변동 폭
$0.202
$1.818
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
명칭
Unicycive Therapeutics Inc
전화
650-384-0642
주소
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-04 | 개시 | Piper Sandler | Overweight |
Unicycive Therapeutics Inc 주식(UNCY)의 최신 뉴스
Thinking about buying stock in Beyondspring, LAVA Therapeutics, - GuruFocus.com
Unicycive Therapeutics Delivers Multiple Poster - GlobeNewswire
Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - StockTitan
Unicycive Therapeutics to Participate in a Fireside Chat at - GlobeNewswire
Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 - StockTitan
This trade activity should not be overlooked: Unicycive Therapeutics Inc (UNCY) - SETE News
Unicycive Therapeutics, Inc. (NASDAQ:UNCY): Is Breakeven Near? - Simply Wall St
A year in review: Unicycive Therapeutics Inc (UNCY)’s performance in the last year - US Post News
Unicycive to present kidney disease therapies at ASN Kidney Week - Investing.com
Unicycive Therapeutics Inc’s Market Journey: Closing Strong at 0.37, Up 3.12 - The Dwinnex
Unicycive to present kidney disease therapies at ASN Kidney Week By Investing.com - Investing.com South Africa
UNCYUnicycive Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Unicycive Therapeutics Announces Late-Breaker Poster - GlobeNewswire
Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 - Yahoo Finance
Unicycive Therapeutics (UNCY) Price Target Increased by 21.14% to 5.41 - MSN
Octagon Capital Advisors LP Acquires New Stake in Unicycive Therapeutics Inc - Yahoo Finance
Octagon Capital Advisors LP Acquires New Stake in Unicycive Ther - GuruFocus.com
H.C. Wainwright & Co. Shares Buy Rating on Biotech Co. - Streetwise Reports
Unicycive reports successful phase 1 kidney drug trial - Investing.com
Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers - The Manila Times
Unicycive reports successful phase 1 kidney drug trial By Investing.com - Investing.com UK
Unicycive Therapeutics Inc (UNCY) is looking forward to a strong quarter - SETE News
UNCY’s earnings forecast for the current quarter - US Post News
Ratio Analysis: Unpacking Unicycive Therapeutics Inc (UNCY)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Unicycive Therapeutics Inc: Weathering Stock Market Storms with 35.62M Market Cap - The InvestChronicle
Get in on Unicycive Therapeutics Inc’s (UNCY) buy-in window today! - SETE News
Unicycive Therapeutics' SWOT analysis: stock potential in kidney disease market - Investing.com
Was anything positive for Unicycive Therapeutics Inc (UNCY) stock last session? - US Post News
What is Unicycive Therapeutics Inc (UNCY) Stock Return on Shareholders’ Capital? - SETE News
Market Recap Check: Unicycive Therapeutics Inc (UNCY)’s Positive Finish at 0.44, Up/Down 2.82 - The Dwinnex
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - ForexTV.com
Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor - EIN News
Unicycive Therapeutics Inc (UNCY) deserves closer scrutiny - US Post News
Unicycive Therapeutics (NASDAQ:UNCY) and Aprea Therapeutics (NASDAQ:APRE) Head to Head Comparison - Defense World
Take off with Unicycive Therapeutics Inc (UNCY): Get ready for trading - SETE News
Examining Unicycive Therapeutics Inc (UNCY) more closely is necessary - US Post News
Three Central African countries commit to global eradication of Guinea-worm disease - WHO | Regional Office for Africa
Upward Trajectory: Unicycive Therapeutics Inc (UNCY) Posts a Slidee, Closing at 0.38 - The Dwinnex
Unicycive Therapeutics to Present at the Virtual Life Sciences Investor Forum on September 19, 2024 - StockTitan
Uxin finds new friend on difficult road to profitability - Bamboo Works
ICMR partners with industry leaders for groundbreaking First-in-Human Phase-1 clinical trials - ETHealthWorld
Views of Wall Street’s Leading Experts on Unicycive Therapeutics Inc - SETE News
Unicycive Therapeutics Inc’s Market Journey: Closing Strong at 0.39, Up 5.51 - The Dwinnex
Unicycive Therapeutics Inc (UNCY) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - The InvestChronicle
Unicycive Therapeutics Inc’s results are impressive - US Post News
Unicycive stock remains Speculative Buy-rated by Benchmark; optimistic on FDA submission - Investing.com
Unicycive Therapeutics Inc (UNCY) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
There is no way Unicycive Therapeutics Inc (UNCY) can keep these numbers up - SETE News
Unicycive Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - The Bakersfield Californian
Shilpa Medicare announces submission of NDA for Oxylanthanum Carbonate to USFDA by Unicycive Therapeutics - Medical Dialogues
Unicycive retains Buy rating, stock target post-NDA submission By Investing.com - Investing.com Canada
Unicycive Therapeutics Inc (UNCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.47%
자본화:
|
볼륨(24시간):